Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2005

01-05-2005 | Short Communication

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment

Authors: Philipp Schütt, Ulrike Buttkereit, Dieter Brandhorst, Monika Lindemann, Sven Schmiedl, Hans Grosse-Wilde, Siegfried Seeber, Mohammad Resa Nowrousian, Bertram Opalka, Thomas Moritz

Published in: Cancer Immunology, Immunotherapy | Issue 5/2005

Login to get access

Abstract

While vaccination with antigen-pulsed dendritic cells (DCs) represents a promising therapeutic strategy in multiple myeloma (MM), clinical benefit, so far, has been limited to individual patients. To identify potential problems with this approach, we have analyzed the influence of treatment parameters, in particular high-dose chemotherapy (HD-CTX) and thalidomide, on in vitro DC generation and peripheral blood lymphocyte subsets in MM patients. From a total of 25 MM patients, including 14 patients on thalidomide treatment and 11 after HD-CTX, in vitro DC generation from peripheral blood monocytes under serum-free condition was investigated. In addition, peripheral blood lymphocyte subsets were assessed in 17 patients including 10 patients on thalidomide treatment and 9 patients after HD-CTX. Efficient in vitro generation of DCs (median 7.1×106/100 ml peripheral blood; range 0.1–42.5×106/100 ml peripheral blood) expressing DC-typical surface markers was observed in 23 MM patients (92%), although reduced expression of CD1a, CD40, CD83, and HLA-DR was observed in patients treated with thalidomide. With respect to lymphocyte subsets, MM patients showed significantly (p<0.05) reduced B and CD4+ lymphocytes in the peripheral blood. This effect was most prominent within 6 months of HD-CTX and in patients receiving thalidomide (usually in combination with CTX). CD8+ lymphocytes were significantly increased in MM patients. Thus, despite the well-known deficiencies in their immune system, adequate numbers of DCs can be generated in most myeloma patients. In patients treated with thalidomide, however, it remains to be seen whether the reduced expression of co-stimulatory molecules has functional relevance.
Literature
1.
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91CrossRefPubMed
2.
Bensinger WI, Maloney D, Storb R (2001) Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 38:243CrossRefPubMed
3.
Bogen B, Schenck K, Munthe LA, Dembic Z (2000) Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncol 39:783CrossRefPubMed
4.
Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C, Strober W, Waldmann T (1975) Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells. N Engl J Med 293:887PubMed
5.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309PubMed
6.
Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta(1) and interleukin-10. Blood 98:2992CrossRefPubMed
7.
Chen B, Stiff P, Sloan G, Kash J, Manjunath R, Pathasarathy M, Oldenburg D, Foreman KE, Nickoloff BJ (2001) Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin Immunol 98:280CrossRefPubMed
8.
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210CrossRefPubMed
9.
Deng L, Ding W, Granstein RD (2003) Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol 121:1060CrossRefPubMed
10.
Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, Chen YT, Jungbluth AA (2003) Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 3:9PubMed
11.
12.
Halapi E, Werner A, Wahlstrom J, Osterborg A, Jeddi-Tehrani M, Yi Q, Janson CH, Wigzell H, Grunewald J, Mellstedt H (1997) T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 27:2245PubMed
13.
Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885CrossRefPubMed
14.
Haslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187:946CrossRefPubMed
15.
Janeway CA Jr, Sakato N, Eisen HN (1975) Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci U S A 72:2357PubMed
16.
Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135PubMed
17.
Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML (1998) Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 161:2804PubMed
18.
Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML (2001) Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97:3466CrossRefPubMed
19.
Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA (2001) Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 98:23CrossRefPubMed
20.
Kelsall BL, Stuber E, Neurath M, Strober W (1996) Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci 795:116PubMed
21.
Koehne G, Zeller W, Stockschlaeder M, Zander AR (1997) Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:149CrossRefPubMed
22.
Liu L, Rich BE, Inobe J, Chen W, Weiner HL (1998) Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol 10:1017CrossRefPubMed
23.
Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN (1972) Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 69:1540PubMed
24.
Mackall CL (2000) T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 18:10CrossRefPubMed
25.
Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV, Leitman SF, Read EJ, Carter CS, Wexler LH, Gress RE (2000) Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 96:754PubMed
26.
Maldonado-Lopez R, Maliszewski C, Urbain J, Moser M (2001) Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 167:4345PubMed
27.
Mohty M, Stoppa AM, Blaise D, Isnardon D, Gastaut JA, Olive D, Gaugler B (2002) Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol 72:939PubMed
28.
Palma JP, Yauch RL, Kang HK, Lee HG, Kim BS (2002) Preferential induction of IL-10 in APC correlates with a switch from Th1 to Th2 response following infection with a low pathogenic variant of Theiler’s virus. J Immunol 168:4221PubMed
29.
Pfeiffer S, Gooding RP, Apperley JF, Goldschmidt H, Samson D (1997) Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol 98:973CrossRefPubMed
30.
Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC (1999) Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi’s sarcoma herpesvirus gene sequences. Blood 93:1487PubMed
31.
Ratta M, Curti A, Fogli M, Pantucci M, Viscomi G, Tazzari P, Fagnoni F, Vescovini R, Sansoni P, Tura S, Lemoli RM (2000) Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients. Exp Hematol 28:931CrossRefPubMed
32.
Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230CrossRefPubMed
33.
Reimer P, Kunzmann V, Wilhelm M, Weissbrich B, Kraemer D, Berghammer H, Weissinger F (2003) Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol 82:263PubMed
34.
35.
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699CrossRefPubMed
36.
Shannon E, Aseffa A, Pankey G, Sandoval F, Lutz B (2000) Thalidomide’s ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 46:175CrossRefPubMed
37.
Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G (1992) Thalidomide’s effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 63:5PubMed
38.
Shannon EJ, Sandoval F (1995) Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31:109CrossRefPubMed
39.
Shannon EJ, Sandoval F, Krahenbuhl JL (1997) Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha. Immunopharmacology 36:9CrossRefPubMed
40.
Shannon EJ, Sandoval FG (2002) Thalidomide can costimulate or suppress CD4+ cells’ ability to incorporate [H3]-thymidine—dependence on the primary stimulant. Int Immunopharmacol 2:1143CrossRefPubMed
41.
Steingrimsdottir H, Gruber A, Bjorkholm M, Svensson A, Hansson M (2000) Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 85:832PubMed
42.
Takenaka H, Maruo S, Yamamoto N, Wysocka M, Ono S, Kobayashi M, Yagita H, Okumura K, Hamaoka T, Trinchieri G, Fujiwara H (1997) Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukoc Biol 61:80PubMed
43.
Twomey JJ (1973) Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 132:562CrossRefPubMed
44.
Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750CrossRefPubMed
45.
Wen YJ, Min R, Tricot G, Barlogie B, Yi Q (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99:3280CrossRefPubMed
46.
Xie J, Wang Y, Freeman ME 3rd, Barlogie B, Yi Q (2003) Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 101:4005CrossRefPubMed
47.
Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043PubMed
Metadata
Title
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment
Authors
Philipp Schütt
Ulrike Buttkereit
Dieter Brandhorst
Monika Lindemann
Sven Schmiedl
Hans Grosse-Wilde
Siegfried Seeber
Mohammad Resa Nowrousian
Bertram Opalka
Thomas Moritz
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2005
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-004-0633-6

Other articles of this Issue 5/2005

Cancer Immunology, Immunotherapy 5/2005 Go to the issue

Original Article

Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-β

Original Article

Induction of specific human primary immune responses to a Semliki Forest virus–based tumor vaccine in a Trimera mouse model

Original Article

Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production

Short Communication

Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis

Opinion Paper

Harnessing host immune responses to preneoplasia: promise and challenges

Review

Immunotherapy for superficial bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits